Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Douglas Pharmaceuticals Limited

Latest From Douglas Pharmaceuticals Limited

Pfizer sells Icagen drug discovery, not compounds

Four years after Pfizer acquired Icagen for $56m, the big pharma sold the drug discovery firm to XRpro Sciences for up to $11m, which would seem to be a big discount if the deal gave the buyer access to compounds generated by Icagen's ion channel biology platform.

Neurology Respiratory

FDA guides on abuse-deterrent opioids; generics direction pending

The FDA on 1 April unveiled its final guidance advising makers of brand-name opioids about what they need to do to obtain abuse-deterrent language in the labeling of their products.


INTERVIEW: Actavis CEO Saunders staying put as Allergan deal nears close

Actavis CEO Brent Saunders has been the head of three different companies in less than two years, but with the $66bn acquisition of Allergan about to close any day now, he told Scrip that he's found the place where he plans to retire.


HPV vaccine discoverer to lead NCI after Varmus exit

With the exit at the end of this month from the National Cancer Institute (NCI) of Dr Harold Varmus, who is stepping down as director after five years to open a research laboratory at Weill Cornell Medical College in New York and serve as an adviser to its dean, Dr Douglas Lowy, the agency's deputy director, will now take the reins as acting chief.

See All

Company Information

  • Industry
  • Biotechnology